The final clinical profile of EOPSP closely resembled that of LOPSP and mirrored previous studies which have shown that initial non‐RS phenotypes come to resemble RS in the latter stages of disease.26 As we move into a new era of potential anti‐tau therapies,27 early and accurate distinction between PSP and PD will become increasingly important. The gene discussed is MAPT; the disease is supranuclear palsy, progressive, 1.